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Background: Abiraterone acetate (AA), a selective inhibitor of the CYP17 enzyme, demonstrated a sig-
niﬁcant improvement in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of endocrine side effects, mainly an increased adrenal mineralocorticoid production, could limit
its use in patients with atrial ﬁbrillation.
Methods: We retrospectively reviewed the clinical records of 85 metastatic castration-resistant prostate
cancer patients treated with AA at our institutions and identiﬁed six patients suffering from concomitant
atrial ﬁbrillation.
Results: In these six patients, themedian duration of AA treatmentwas 11.5months (range 4e22months)
with a biochemical response in three patients. No signiﬁcant cardiac events were observed during the
treatment.
Conclusion: Our data suggest that AA may be safely administered in patients with atrial ﬁbrillation.
Copyright © 2016 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
As most cases of prostate cancer are diagnosed in patients aged
> 70 years,1 the development of metastatic castration-resistant
prostate cancer (mCRPC) is generally observed in senior adults
whose burden of comorbidities, mainly cardiovascular, leads to
more frequent physical frailty and a higher risk of treatment-
related side effects.2
Abiraterone acetate (AA) is a selective and irreversible inhibitor
of CYP17, a microsomal enzyme involved in testosterone synthesis
in the testis, adrenal glands, and the tumor itself.3 AA demonstrated
an overall survival improvement in mCRPC patients, both in a ﬁrst
and second line setting.4,5
Consistently to its mechanism of action, the AA toxicity proﬁle is
related to mineralocorticoid excess potentially leading to hyper-
tension, hypokalemia, and ﬂuid retention. Inhibition of CYP17l Medicine, “F. Tappeiner”
ciﬁc Prostate Society, Published breduces cortisol levels and, consequently, produces a compensatory
ﬂare of adrenocorticotropic hormone associated with secondary
hyperaldosteronism. These side effects can be readily managed by
adding low-dose steroids. Nevertheless, clinically signiﬁcant heart
disease, atrial ﬁbrillation (AF), or other cardiac arrhythmias repre-
sented exclusion criteria in AA pivotal trials.4,5 At the same time,
these conditions are frequently encountered in clinical practice due
to the increasing age proﬁle of mCRPC patients. The prevalence and
incidence of AF increase with age and are higher in men than in
women, with 6.9% of men aged 70e74 years suffering from this
arrhythmia.6 As the mean age of mCRPC patients is 71 years,7 AF
can be common in these patients.
Procopio et al8 evaluated the safety proﬁle of AA in 51 patients
with mCRPC and concomitant cardiovascular risk factors. Three of
them suffered from cardiac arrhythmia not further speciﬁed. The
authors concluded that AA appears to be safe and well tolerated
even in patients with cardiovascular comorbidities or with an
increased risk for cardiovascular disease. To date, the literature did
not provide further data about the AA safety proﬁle in patients with
cardiovascular comorbidities, especially AF. The aim of the presenty Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Table 1
Ecocardiographic parameters
Patient 1 Patient 2 Patient 3
Left ventricular ejection
fraction (%)
Pretreatment > 60 > 60 59
At 6 moa) > 60 > 60 > 60
Left ventricular end-diastolic
diameter (mm)
Pretreatment 60 52 58
At 6 moa) > 60 51 55
Left atrial volume (mL/m2) Pretreatment 39 27 31
At 6 moa) 56 44 43
End-diastolic interventricular
septum (mm)
Pretreatment 14 13 13
At 6 moa) 15 13 12
Clinically relevant valvulopathy Pretreatment No No No
At 6 moa) No No No
a) After beginning treatment with abiraterone acetate.
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concomitant paroxysmal or permanent AF.
2. Materials and methods
Patients with mCRPC treated with AA after docetaxel failure
were prospectively followed at our institutions. All these patients
received once-daily oral treatment with AA 1,000 mg (four 250 mg
tablets) plus prednisone at a dose of 5 mg twice daily until pro-
gression. Furthermore, if clinically indicated, patients underwent a
baseline cardiologic examination with electrocardiography and
echocardiographic assessment.
3. Results
In our institutions between May 2013 and September 2015, a
total of 85 mCRPC patients received AA after docetaxel failure. Six
(7.1%) patients with a median age of 75.5 years (range 59e85 years)
had a history of permanent (n ¼ 4) or paroxysmal (n ¼ 2) AF at the
initiation of AA treatment. All patients showed a normal cardiac
ejection fraction before treatment without signiﬁcant valvular
heart disease. The mean CHADS-VASc score was 3.2 (range 2e5).
Concomitant cardiovascular medications consisted of beta-blockers
(bisoprolol, n ¼ 1; atenolol, n ¼ 1; sotalol, n ¼ 1), anticoagulants
(phenprocoumon, n ¼ 5; low-molecular-weight heparin, n ¼ 1),
diuretics (loop diuretics n ¼ 2, Indapamid n ¼ 1), and antihyper-
tensives (ramipril, n ¼ 2; enalapril, n ¼ 1; losartan, n ¼ 2; telmi-
sartan, n ¼ 1; amlodipin, n ¼ 2; diltiazem, n ¼ 1; manidipin, n ¼ 1).
In addition, four of these six patients had concomitant Type 2
diabetes mellitus. The median duration of AA treatment in patients
with AF was 11.5 months (range 4e22 months), with a biochemical
response in three patients. Three patients repeated echocardiog-
raphy after 6 treatment months (Table 1). The only change was
observed in the left atrial volume, which increased from a mean of
32 mL/m2 to 48 mL/m2, corresponding to an increase of 50%. Left
atrial enlargement is associated with an increased risk for stroke
and cardiovascular death.9e11 Although the increase in left atrial
volume observed in our study could reﬂect ﬂuid retention and thusbe related to AA treatment, it is also known that the natural history
of atrial ﬁbrillation itself is characterized by left atrial structural
changes.12 However, the increase in left atrial volume observed in
our patients had no clinical impact during the follow-up period. In
addition, no grade 1e4 adverse cardiac events were observed and
no signiﬁcant adjustment in the antihypertensive or diuretic
medication was necessary.
4. Discussion
In our report, no adverse cardiac event was observed in patients
with mCRPC and concomitant atrial ﬁbrillation being treated with
AA. However, due to the small case number the present data do not
allow deﬁnitive conclusions regarding the safety of AA in patients
with atrial ﬁbrillation. Further studies with larger patient cohorts
and long-term follow up are warranted. A close monitoring of
baseline echocardiography in combinationwith cardiac biomarkers
(e.g. BNP) should be performed prior and during the treatmentwith
AA in this unique patient population.
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